Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TT301 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| TT301 | EXPERIMENTAL | Investigational drug TT301 |
| Placebo | PLACEBO_COMPARATOR | Normal saline |
| Name | Type | Description |
|---|---|---|
| TT301 | DRUG | Single iv dose of TT301 |
| Placebo | DRUG | Single iv dose of 0.9% sodium chloride for injection USP |
Inclusion Criteria: * Male * 18 to 40 years, inclusive * 55 - 95 kg, inclusive Exclusion Criteria: * Evidence of any clinically significant disease * History of cancer * History of syncope or severe vasovagal events * Antibiotic treatment within 60 days of Day 1 * Surgical procedure within 60 day...
TT301 is an investigational small molecule being developed for traumatic brain injury. It is currently in Phase 1 clinical development and has not been approved by the FDA. The drug is being studied for its effects on cytokine levels following an endotoxin challenge in healthy volunteers.
TT301 is being developed by Opko Health Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol OPK. The drug is currently in Phase 1 clinical development for traumatic brain injury.
TT301 is in Phase 1 clinical development. It has completed one Phase 1 trial, which was a randomized, double-blind, placebo-controlled study. The drug is investigational and has not been approved by the FDA.
TT301 has one completed clinical trial, NCT01357421, titled 'Effects of TT301 on Cytokine Levels Post Endotoxin Challenge.' This Phase 1 study enrolled 18 healthy male volunteers in the United States and was placebo-controlled.
TT301 is a small molecule being studied for traumatic brain injury. The completed Phase 1 trial evaluated its effects on cytokine levels following an endotoxin challenge, suggesting it may modulate inflammatory responses. However, its specific molecular target has not been disclosed.